Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Multidisciplinary Care for Lymphatic and Venous Disorders
Lymphatic and venous disorders often have profound functional and psychological implications for patients and their families. Caring for patients with edema is a complex task requiring input from many specialists. To meet these challenges, the Stanford Center for Lymphatic and Venous Disorders provides a broad spectrum of diagnostic and therapeutic treatments for adults and children.
Care and Treatment of Lymphatic and Venous Disorders
Our center is actively recruiting patients for the following research protocols:
Based upon exciting preliminary animal studies, we believe that we have an effective and safe drug treatment strategy to prevent the appearance of lymphedema in patients at risk. This is a placebo controlled trial, in which active treatment occurs for one year following enrollment in the study. Periodic follow up visits following the first year of participation will be available at Stanford.
Lymphedema drug treatment
We have evidence from past animal studies that we have a safe drug treatment strategy to help restore lymphedema tissues toward normal. This is a double-blinded placebo controlled protocol, in which lymphedema patients are randomized to receive either the placebo or drug treatment. Patients receiving placebo will have the opportunity to receive a prescription for the active study medication at the end of the four month trial (as deemed appropriate by Dr. Rockson).
Recombinant human hyaluronidase
This pilot phase I/II trial studies the side effects and the best dose of recombinant human hyaluronidase (rHuPH20), and to see how well it works in treating lymphedema in patients with a history of breast cancer. Our approach uses the strategy of injecting recombinant human hyaluronidase in the subcutaneous space of the arm, to free excess fluid for reuptake into the small blood vessels. Recombinant human hyaluronidase may reduce limb edema size in patients with lymphedema. rHUPH20 marketed as Hylenex®, and is FDA approved for subcutaneous administration.
Do you know if you're at risk for heart disease? How healthy is your heart? In recognition of American Heart Month this February, stay heart healthy and celebrate your heart with us.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Stanford Health Care is known worldwide for the advanced patient care provided by its doctors and staff. We also provide a wide range of guest services and amenities to our patients and visitors. Learn more about preparing for a hospital stay, billing and financial services, and our other support programs in Patients & Visitors.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
HOW TO REFER
Fax a referral form with supporting documentation to 650-320-9443.
Track your patients' progress and communicate with Stanford providers securely online.